secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2026-08-10T20:03:56+00:00
Accession:  0001193125-26-342328
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna Q2 2026: net loss $13.0M, cash $516.5M, SEP-479 half-life supports once-daily dosing
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities totaled $516.5M as of June 30, 2026; expected to fund operations into 2029.
- Q2 2026 revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex a year ago; net loss narrowed to $13.0M from $24.8M.
- SEP-479 Phase 1 observed elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 showed positive Phase 1 results; company evaluating signal-finding studies in mast cell-driven diseases; TSHR program advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/0001193125-26-342328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer